Nelli
AI-powered video/audio seizure detection system combining machine learning with expert review
Device · HybridCompany source
Company profile
About Neuro Event Labs OY
Neuro Event Labs is a global healthcare diagnostics company pioneering AI motion diagnostics for epilepsy monitoring. The company's flagship product, Nelli®, is the world's first non-contact, AI-driven video and audio monitoring system designed to identify and prioritize the review of seizure events with positive motor components. Nelli analyzes audio/video recordings captured via a Personal Recording Unit (PRU) with camera and microphone to identify events indicative of motor seizures. The system uses machine learning algorithms to detect relevant moments, creating an interactive report for physician review. Neuro Event Labs also offers an optional service for expert review by credentialed clinical staff. The technology has demonstrated 88% sensitivity for all motor seizures and 95.2% sensitivity for convulsive seizures in European in-hospital validation studies. Nelli is FDA 510(k) cleared for use in the United States, CE marked as a Class IIa medical device in the European Union under MDR, and registered as a Class IIa device in the United Kingdom. The system serves both hospital and at-home monitoring environments, enhancing current diagnostic and follow-up methods for epilepsy patients. Neuro Event Labs has received funding from the European Union's Horizon 2020 research and innovation programme and has established partnerships with leading epilepsy centers including Newcastle Royal Victoria Infirmary and Filadelfia Epilepsy Hospital in Denmark.
Company description Neuro Event Labs OY official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Neuro Event Labs OY?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- convulsive seizures
- epilepsy
- motor seizures
- pharmacoresistant epilepsy
- seizures
Who it serves
- Clinics
- Epilepsy Centers
- Health Systems
- Hospitals
Deployment & integration
Hybrid · On Premise deployment with recorded integration context.
Geographic context
MarketsCornwall UK · Denmark · European Union · Finland · Sweden · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA 510(k) clearance November 2025, €2.0M funding round February 2025, EU MDR certification December 2024, Newcastle Royal Victoria Infirmary partnership March 2026, FDA Breakthrough Device Designation
Partnerships
Recorded partners
- Cornwall UK healthcare facilities
- Danish Epilepsy Centre Dianalund
- Filadelfia Epilepsy Hospital Denmark
- Linköping University Hospital
- Newcastle Royal Victoria Infirmary
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Nelli Pro
Hospital-wide AI-powered seizure monitoring system for inpatient epilepsy units
Platform · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Automatic assessment of the myoclonus severity from videos recorded according to standardized Unified Myoclonus Rating Scale protocol and using human pose and body movement analysis.Seizure · Jan 24, 2020
Automated pose estimation captures key aspects of General Movements at eight to 17 weeks from conventional videos.Acta paediatrica (Oslo, Norway : 1992) · Oct 1, 2019
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Nelli (Version 7.11)K251506 · 510k · Nov 21, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
88% sensitivity for all motor seizures
European in-hospital validation study with 230 patients
95.2% sensitivity for convulsive seizures
European in-hospital validation study with 230 patients
6.48 false detection rate per hour for all motor seizures
European in-hospital validation study
86% clinical decisions
Study with 104 patients monitored average 29 days
83% differential diagnosis
Study with 104 patients
68% therapeutic interventions or adjustments
Study with 104 patients
Newcastle Royal Victoria Infirmary
At-home patient monitoring project for adults with intellectual disabilities and epilepsy, funded by NIHR, to recognize complex seizures and reduce unnecessary emergency and hospital interactions
Established as Nelli's Centre of Excellence
Linköping University Hospital
Evaluation of diagnostic yield and clinical utility of Nelli in patients with pharmacoresistant epilepsy
Prospective exploratory study published in Epilepsy and Behavior demonstrating clinical utility
Cornwall UK Community Care
Improving nocturnal event monitoring in people with intellectual disability in community settings
Proven highly effective in supporting care for vulnerable population with intellectual disabilities
Danish Epilepsy Centre
Validation study of Nelli against video-electroencephalogram monitoring in 230 patients aged 0-80 years
88% sensitivity for all motor seizures, 95.2% sensitivity for convulsive seizures, 6.48 false detection rate per hour
Filadelfia Epilepsy Hospital
Implementation of Nelli Pro monitoring system across all hospital beds for pediatric, adult and epilepsy monitoring units
Deployed across all 46 hospital beds at Dianalund facility
Multi-site Clinical Study
104 patients monitored for average of 29 days using Nelli for clinical decision support
86% led to clinical decisions, 83% differential diagnosis of patients with recorded episodes, 68% therapeutic interventions or adjustments
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Rod Williams
CEO
06 · Company updates
Updates from Neuro Event Labs OY
Recent articles published on Neuro Event Labs OY's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.